18 June 2002
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.Nicolas Tsavaris, Christos Kosmas, Haralambos P Kalofonos
Med Sci Monit 2002; 8(6): PI58-63 :: ID: 420797
BACKGROUND: Docetaxel has been the only single agent with proven activityand documented survival benefit in the second-line treatment of advanced/refractory non-small cell lungcancer (NSCLC). Combinations of docetaxel with other active agents in this setting, such as gemcitabine,besides their popularity as front-line treatment, are currently being explored in an attempt to improvethe results over single-agent docetaxel in relapsed/refractory NSCLC.MATERIAL/METHODS: Given the establishedactivity of single-agent docetaxel in two recent large randomized phase III trials against best supportivecare or versus single-agent Vinorelbine or Ifosfamide in patients with platinum pretreated NSCLC, andthe proven activity of single-agent gemcitabine in this setting, combination regimens employing thesetwo agents in various doses and schedules have recently been initiated. Adequately designed phase IIstudies using standard criteria of efficacy and safety, with peer-review based publication, were selectedfrom the literature.RESULTS: The gemcitabine/docetaxel combination in various schedules with or withoutG-CSF support as salvage therapy of NSCLC pre-treated with platinum+paclitaxel-based regimens has beenevaluated in four recently published phase II clinical studies, and has been shown to represent a tolerableand active regimen in this setting, yielding a 10-33% response rate, improvement of disease-related symptoms,and meaningful median and 1-year survival figures in the range of 20-32%. Improvement of disease-relatedsymptoms has outweighed toxicity in all these studies.CONCLUSIONS: Randomized studies are warranted,comparing the gemcitabine/docetaxel combination to single-agent gemcitabine or docetaxel, drugs currentlyrecommended in the second-line treatment of advanced NSCLC.
Keywords: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase II, Deoxycytidine, Lung Neoplasms, paclitaxel, Salvage Therapy, Taxoids
01 August 2022 : EditorialEditorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 Pandemic
Med Sci Monit 2022; 28:e937927
05 Aug 2022 : Clinical ResearchA Retrospective Study of 98 Elderly Patients with High-Risk Lateral Femoral Wall Intertrochanteric Hip Frac...
Med Sci Monit In Press; DOI: 10.12659/MSM.936923
05 Aug 2022 : Clinical ResearchHemoglobin/Red Blood Cell Distribution Width Ratio in Peripheral Blood Is Positively Associated with Progno...
Med Sci Monit In Press; DOI: 10.12659/MSM.937146
04 Aug 2022 : Clinical ResearchRadiological Assessment of Prevalance and Quality of Periapical Status of Endodontic Treatments
Med Sci Monit In Press; DOI: 10.12659/MSM.936569
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292